Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis

NCT07693400 — Phase 2, Active not recruiting, 44 participants, Taiwan Municipal An-Nan Hospital-China Medical University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Efficacy of Distal Topical Application of a Traditional Chinese Medicinal Ingredient for Atopic Dermatitis and Its Exosome-Mediated Regulatory Mechanisms: Basic and Clinical Studies

RegistryNCT07693400
StatusActive not recruiting
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: quadruple, treatment
Enrollment44 (Estimated)
SponsorTaiwan Municipal An-Nan Hospital-China Medical University (Other); collaborators: China Medical University, Taiwan
ConditionsAtopic Dermatitis (AD)
Interventionsmenthol-based hand and foot gloves, Sham menthol-based hand and foot gloves (Drug)
Datesstart 2026-04-29, primary completion 2028-02-16 (estimated), completion 2028-02-16 (estimated), first posted 2026-07-09, last updated 2026-07-09
Locations1 site in Taiwan

Related Papers Related Patents Related Grants Related Experts
All trials for Atopic Dermatitis (AD) All trials of menthol-based hand and foot gloves All trials of Sham menthol-based hand and foot gloves

-Summary

The goal of this clinical trial is to learn if menthol works to relieve pruritus in atopic dermatitis. The primary objectives are to evaluate the safety and clinical efficacy of menthol-containing gloves and foot-covers, specifically whether they can improve patient-reported Peak Pruritus Numerical Rating Scale (PP-NRS). Secondary objectives include assessing the Eczema Area Severity Index (EASI), the Dermatology Life Quality Index (DLQI), biochemical examinations (including white blood cell count, hemoglobin, GOT, GPT, creatinine, platelet count, and HbA1c), and exosome analysis. Participants will be asked to: Wear menthol-containing gloves and foot-covers (or shams) for 5 minutes per session, following a schedule of 5 consecutive days of use and 2 days of rest each week, over a total period of 28 days. Attend clinic visits on Days 1, 14, 28, and 42 for evaluations and tests.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
8% menthol groupExperimentalDrug: menthol-based hand and foot glovesParticipants will undergo a four-week intervention, wearing the menthol gloves for five minutes once daily, following a five-days-on, two-days-off weekly schedule. Follow up the two-week tracking period of not wearing gloves.
sham menthol groupSham comparatorDrug: Sham menthol-based hand and foot glovesParticipants will undergo a four-week intervention, wearing the menthol gloves for five minutes once daily, following a five-days-on, two-days-off weekly schedule. Follow up the two-week tracking period of not wearing gloves.
  • menthol-based hand and foot gloves (Drug): Participants will undergo a four-week intervention, wearing the menthol gloves for five minutes once daily, following a five-days-on, two-days-off weekly schedule. Follow up the two-week tracking period of not wearing gloves.
  • Sham menthol-based hand and foot gloves (Drug): Participants will undergo a four-week intervention, wearing the menthol gloves for five minutes once daily, following a five-days-on, two-days-off weekly schedule. Follow up the two-week tracking period of not wearing gloves.

+Outcome measures

Primary outcomes

  • The Peak Pruritus Numerical Rating Scale (PP-NRS) [PP-NRS will be assessed at Baseline (Day 1), Day 14, Day 28 (end of intervention), and Day 42 (end of study).]: This scale uses an 11-point score, from 0 (no itch) to 10 (worst imaginable itch). The scale evaluates the peak pruritus during the past 24 hours.

Secondary outcomes

  • The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) [vIGA-AD will be assessed at Baseline (Day 1), Day 14, Day 28 (end of intervention), and Day 42 (end of study).]: It utilizes a 5-point ordinal scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). Each score is anchored to specific morphologic descriptors of skin findings, such as erythema, induration/papulation, oozing/crusting, and lichenification.
  • Eczema Area Severity Index (EASI) [EASI will be assessed at Baseline (Day 1), Day 14, Day 28 (end of intervention), and Day 42 (end of study).]: EASI is a standardized tool used to assess the severity of AD. The score integrates the involved body surface area and the severity of skin lesions. Four body regions, including the head and neck, arms, trunk, and legs, are evaluated separately. Each region is assigned a score from 1 to 6 based on the percentage of involvement. Four clinical signs, erythema, papulation or edema, excoriation and lichenification, are rated from 0 to 3. The final EASI score is calculated by the summing of the 4 regional scores, from 0 to 72.
  • The Dermatology Life Quality Index (DLQI) [DLQI will be assessed at Baseline (Day 1), Day 14, Day 28 (end of intervention), and Day 42 (end of study).]: The index consists of ten questions with four possible responses: 'not at all', 'a little', 'a lot' or 'very much' with corresponding scores of 0, 1, 2, and 3 \[48\]. The total score ranges from 0 to 30.

+Eligibility

Sex: All, ages: 12 Years to 100 Years

Inclusion Criteria:

* 1\. Age 12 years or above.
* 2\. Clinical diagnosis of atopic dermatitis based on Hanifin and Rajka criteria.
* 3\. Pruritus severity defined as PP-NRS ≥ 4.
* 4\. Signed the informed consent form that has been approved by the Institutional Review Board.
* 5\. No changes in AD medications within four weeks before enrollment and no change in dosage during the study period.

Exclusion Criteria:

* 1\. Allergy to menthol.
* 2\. Marked fluctuation of AD symptoms.
* 3\. Secondary infection of skin lesions.
* 4\. Severe peripheral vascular disease, skin lesions, or severe edema at hands/feet.
* 5\. Pregnancy or breastfeeding.
* 6\. Severe psychiatric conditions.
* 7\. With conditions such as uremia, cirrhosis, congestive heart failure with pulmonary edema, coagulation disorders, epilepsy, alcoholism, drug abuse.
* 8\. Unable to comply with the study protocol or unwilling to provide written consent.
* 9\. Participation in another clinical study within the previous month. The research team may also exclude any participant who is considered unsuitable for the study.

+Locations (1)

FacilityCityCountryStatus
An Nan Hospital, China Medical UniversityTainan, TaiwanTaiwan

+Publications

  • Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, Rossi AB, Brignoli L, Saba G, Guillemin I, Fenton MC, Auziere S, Eckert L. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021 Apr;126(4):417-428.e2. doi: 10.1016/j.anai.2020.12.020. Epub 2021 Jan 6. PMID 33421555
  • Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014 Jan;69(1):17-27. doi: 10.1111/all.12268. Epub 2013 Oct 14. PMID 24117677
  • Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020 Aug 1;396(10247):345-360. doi: 10.1016/S0140-6736(20)31286-1. PMID 32738956